Article info
PDFImage of the moment
Guess Who: dopamine agonist and creativity?
- Correspondence to Dr Paula Pérez-Torre, Neurology, Hospital Ramon y Cajal, Madrid, Spain; paulaptorre{at}gmail.com
Citation
Guess Who: dopamine agonist and creativity?
Publication history
- Accepted September 8, 2021
- First published November 10, 2021.
Online issue publication
November 18, 2021
Article Versions
- Previous version (10 November 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Clinical - genetic model predicts incident impulse control disorders in Parkinson 's disease
- Dopamine dysregulation syndrome in Parkinson ’s disease: a systematic review of published cases
- Extrastriatal dopaminergic changes in Parkinson ’s disease patients with impulse control disorders
- Increased risk of impulse control symptoms in Parkinson 's disease with REM sleep behaviour disorder
- Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
- Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management
- Sleep disturbance and impulsive - compulsive behaviours in Parkinson 's disease
- Too much of a good thing: hedonistic homoeostatic dysregulation and other behavioural consequences of excessive dopamine replacement therapy in Parkinson ’s disease
- Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease
- Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN - PD trial